Chemotherapy for hormone-refractory prostate cancer-Reference-Cited by-同舟云学术

Chemotherapy for hormone-refractory prostate cancer

Published:2006-10-18 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Shelley Mike¹,Harrison Craig²,Coles Bernadette³,Stafforth John⁴,Wilt Timothy⁵,Mason Malcolm⁶

Affiliation:

1. Velindre NHS Trust; Cochrane Prostatic Diseases and Urological Cancers Unit, Research Dept; Velindre Road Whitchurch Cardiff Wales UK CF4 7XL

2. Velindre NHS Trust; Cardiff Wales UK CF14 2TL

3. Cardiff University ; Cancer Research Wales Library; Velindre Cancer Centre Whitchurch Cardiff UK CF14 2TL

4. Velindre NHS Trust; Research Department; Velindre Road Whitchurch Cardiff Wales UK CFIL2TL

5. VAMC; General Internal Medicine (111-0); One Veterans Drive Minneapolis Minnesota USA 55417

6. Velindre Hospital; Clinical Oncology; Whitchurch Cardiff UK CF4 7XL

Publisher

Wiley

Subject

Pharmacology (medical)

Reference127 articles.

1. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer;Abratt;Annals of Oncology,2004

2. A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents;Akaza;Japanese Journal of Clinical Oncology,1988

3. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer;Albrecht;British Journal of Cancer,2004

4. Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: A prospective randomized study;Anderstrom;European Urology,1995

5. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic horlone refractory prostate cancer;Berry;Journal of Urology,2002

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer;Cancer Drug Resistance;2023-09-25

2. Medicago Sativa Defensin1 as a tumor sensitizer for improving chemotherapy: translation from anti-fungal agent to a potential anti-cancer agent;Frontiers in Oncology;2023-05-26

3. Pharmacological Efficacy of Repurposing Drugs in the Treatment of Prostate Cancer;International Journal of Molecular Sciences;2023-02-19

4. Optimized Therapeutic 177Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer;Pharmaceuticals;2022-12-09

5. Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer;Frontiers in Oncology;2022-07-04